Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects ...
There are multiple chapters near you. Select your preferred chapter.
The FDA told the San-Francisco based biotech to halt the PALIZADE study (NCT05781750), a Phase IIb trial investigating ...
Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...
The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...
The Lupus Research Alliance (LRA) is excited to announce the first-ever recipients of the Translational Bridge Award (TBA), ...
Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, ...
Abstract #2580: Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study 2:15-2:30 PM Room 146AB Tuesday ...
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial Abstract #0662: Deucravacitinib, a First-in-Class ...
Sixteen presentations of preclinical studies funded by the Lupus Research Alliance (LRA) to advance understanding of lupus and potential treatment pathways, including four oral presentations Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback